EGF and HB-EGF modulate inward potassium current in human bladder urothelial cells from normal and interstitial cystitis patients

Yan Sun, Yingying Chen, Benjamin H. Lowentritt, P. Sean Van Zijl, Kristopher R. Koch, Susan Keay, J. Marc Simard, and Toby C. Chai

Department of Surgery, Division of Urology, University of Maryland School of Medicine, Baltimore, Maryland

Submitted 26 April 2006; accepted in final form 5 July 2006

Interstitial cystitis (IC) is an idiopathic condition characterized by bladder hyperalgesia. Studies have shown cytokine and purinergic signaling abnormalities in cultured bladder urothelial cells (BUC) from IC patients. We performed single-cell electrophysiological studies in both normal and IC BUC. A strongly inward rectifying potassium current with conductance of the Kir2.1 channel was identified in normal BUC. This current was significantly reduced in IC BUC. Kir2.1 protein and mRNA were detected in both IC and normal BUC. Epidermal growth factor (EGF) caused a dose-dependent decrease in the inward potassium current in normal BUC. EGF is secreted in higher amounts by IC BUC and is known to decrease Kir2.1 conductance by phosphorylation of Kir2.1. Genistein, a nonspecific phosphatase inhibitor, increased the inward potassium current in normal BUC. EGF reduced the inward potassium current in normal BUC. Treatment of IC BUC with heparin-binding epidermal growth factor-like growth factor (HB-EGF), previously shown to be secreted in lower amounts by IC BUC, significantly increased inward potassium current. These data show that the inward potassium current in BUC can be modulated by EGF and HB-EGF. Changes in BUC membrane potassium conductance caused by altered levels of EGF and HB-EGF may therefore play a role in the pathobiology of IC.

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
findings suggest that potassium currents caused by alterations in growth factor levels could play a role in the pathophysiology of IC BUC function. Future novel therapeutic interventions in hyperalgesic bladder conditions such as IC and possibly OAB could target abnormalities in BUC membrane channel properties.

MATERIALS AND METHODS

Patient selection. The diagnosis of IC was made in patients who met National Institute of Diabetes and Digestive and Kidney Diseases criteria for IC (8). Control (normal) patients had no voiding symptoms by history and showed no glomerulations after bladder hydrodistention.

Human urothelial cell culture. The protocol to obtain cystoscopic bladder urothelial biopsies for cell culture was approved by the Institutional Review Board of University of Maryland at Baltimore. All study patients were counseled, gave informed consent, and had their bladders biopsied. The process of cell culture from cystoscopic urothelial biopsies has been described previously (32). In brief, cystoscopic cold-cup bladder urothelial biopsies were performed under regional or general anesthesia. These specimens were transported to the laboratory within 30 min. They were then minced manually into 0.5-mm pieces. The samples were placed in uncoated plastic tissue culture plates (Falcon, Franklin Lakes, NJ) containing complete cell medium composed of MEM plus l-glutamine (Mediatech, Herndon, VA) supplemented with 1 U/ml insulin, 10% heat-inactivated FBS, 1.25 g/ml streptomycin (GIBCO BRL, Grand Island, NY). Samples were anchored to the bottom of the well with sterile penicillin, and 100 g/ml amphotericin B, 100 U/ml streptomycin (GIBCO), and 10% heat-inactivated FBS, 1.25 g/ml streptomycin (GIBCO BRL, Grand Island, NY). Samples were anchored to the bottom of the well with sterile cover glass slips and incubated in 95% air-5% CO2 at 37°C. The samples were quickly in liquid nitrogen.

Electrophysiology of BUC. Experiments were carried out on cultured BUC serum starved at least 12 h before the electrophysiological recording. Membrane currents were amplified (Axopatch 200A; Axon Instruments, Foster City, CA) and sampled online at 5 kHz with the use of a microcomputer equipped with a digitizing board (Digidata 1200A; Axon Instruments) and running Clampex software (version 8.0; Axon Instruments). Macroscopic currents were recorded in intact cells by using the conventional whole cell configuration. Single-channel currents were recorded in cell-attached membrane patches. Patch-clamp pipettes, pulled from borosilicate glass (Kimax; Fisher Scientific, Pittsburgh, PA), had resistances of 4–5 MΩ for single-channel recordings and 2–3 MΩ for experiments using the conventional whole cell technique. The bath electrode was an Ag-AgCl pellet (Clark Electromedical, Reading, UK) that was placed directly in the bath. Cells with seal resistances <3 GΩ and access resistances >50 MΩ were discarded. Membrane currents were measured during step pulses (200 or 600 ms) or during ramp pulses (0.38 mV/ms) from a holding potential of −80 mV. All experiments were performed at room temperature, 20–22°C. For the experiment in Fig. 1B, macroscopic currents were measured during step pulses (600 ms) from a test potential of −140 mV to 10 mV at 10-mV intervals. The outward current was the focus of Fig. 2A, so the test potential was from −70 to 80 mV.

For some experiments (Fig. 1C), we used cell-attached patches to measure single-channel currents. For these experiments, calculation of the reversal potential (Erev) of a channel requires knowledge of the actual cell membrane potential (Evm). Experiments were carried out assuming Erev = −67 mV. After single-channel data collection, the recording was converted from a cell-attached to a conventional whole cell configuration to measure Evm. The mean value of Erev measurement was used to compute the proper value of Evm, for the single-channel recordings (23).

Recording solutions. For whole cell and cell-attached recordings, we used a bath solution containing (in mM) 135 NaCl, 10 KCl, 1 CaCl2, 1.2 MgCl2, 10 HEPES, and 10 glucose, pH 7.4. The pipette solution contained (in mM) 145 KCl, 1 MgCl2, 0.2 CaCl2, 5 EGTA, 10 HEPES, pH 7.2. The measured osmolality of the pipette solutions was ~295 mosmol/l, and that of the extracellular solution was ~300 mosmol/l (Precision Systems, Natick, MA). Tetrodotoxin, charybdotoxin, and iberiotoxin were obtained from Calbiochem (San Diego, CA). 4-Aminopyridine (4-AP) was obtained from Sigma (St. Louis, MO).

Holding currents were not subtracted from recordings. Single-channel amplitudes used to calculate slope conductance were obtained by fitting a Gaussian function to an all-points amplitude histogram of records obtained at various potentials. Statistical analysis was carried out using Student’s t-test for unpaired samples (Origin 7.0; Microcal Software, Northampton, MA). Data are given as means ± SE.
Fig. 2. Outward currents in normal BUC. A: BUC possessed a relatively large outward current. B: outward currents could be partially blocked by 100 nM charybdotoxin. C: charybdotoxin-insensitive currents could be further blocked by 5 mM 4-aminopyridine (4-AP).

SDS-PAGE and Western blot analysis for Kir2.1 and BK. Cultured cells were treated with 0.25% trypsin for 15 min to release them from their plates. The cells were retrieved by centrifuge and washed three times with cold PBS buffer. Rat kidney homogenate served as a positive control for inward rectifying potassium channel subfamily 2.1 (Kir2.1) current and large-conductance calcium-activated potassium channel (BK) current. Cell pellets were then lysed with ice-cold denaturing buffer and incubated on ice for 1 h. The entire cell lysate was used for this experiment. Protein quantification was determined using Bio-Rad protein assay kit according to the manufacturer’s protocol. We performed 10% SDS-PAGE with 50–70 μg of protein loaded for each sample. Once SDS-PAGE was finished, the gel was electrotransferred to polyvinylidene difluoride membranes and blotted for 1 h with 5% nonfat milk blocking solution in Tween-containing Tris-buffered saline (TBST) buffer. The membrane was incubated overnight at 4°C with 1:100 rabbit anti-human Kir2.1 antibody (Alomone Labs, Jerusalem, Israel) or 1:300 rabbit anti-mouse BK antibody (Alomone Labs) in TBST buffer containing 5% nonfat milk. The following day, the membranes were washed with TBST, incubated for 2 h at room temperature with corresponding anti-rabbit secondary antibody (1:1,000), and then visualized with enhanced chemiluminescence reagents. For molecular mass determination, SDS-PAGE was performed together with prestained standard protein markers with molecular mass range between 250 and 10 kDa. Membranes were subsequently incubated with 1:25,000 actin antibody to validate the technique.

RT-PCR and PCR for Kir2.1 transcript. RT-PCR was performed to assess the mRNA level for Kir2.1 for IC and normal BUC. Total RNA from BUC were harvested using Trizol reagent (GIBCO) according to the manufacturer’s instructions. First-strand cDNA synthesis was performed using total RNA primed with oligo(dT)12–18. Superscript II according to the manufacturer’s instructions. First-strand cDNA synthesis was performed using total RNA primed with oligo(dT)12–18. Superscript II according to the manufacturer’s instructions.

PCR reactions were performed in 50-μl final volumes containing 2 μl of cDNA, 0.5 μM of each primer, 200 μM dNTPs, 2.5 units of Taq DNA polymerase, and 1× Taq DNA polymerase reaction buffer (Promega, Madison, WI). The PCR primer sequences used for Kir2.1 transcript amplification sequence were 5′-GAAGTCACACCCGACAACAGTG-3′ and 5′-TTCTGGATTTGAGGAGCTGTGC-3′ for an expected amplicon size of 600 bp (12). The PCR conditions used were 5 min at 95°C and 40 cycles for 1 min at 95°C, 1 min at 54°C (Kir2.1) or 60°C (glyceraldehyde-3-phosphate dehydrogenase, GAPDH), and 1 min at 72°C, with extension conditions of 10 min at 72°C.

GAPDH served as a positive control, and negative controls included amplifications performed using specific primers in the absence of cDNA and amplifications that included cDNA but not specific primers. In addition, amplification was performed on RT product obtained from pipette solution aspirate without cells. PCR products were electrophoresed on 1.2% agarose gels and stained with ethidium bromide.

Fluorescence-activated cell sorting analysis for Kir2.1. Flow cytometry techniques were used and fluorescence-activated cell sorting (FACS) analysis was performed to quantify the expression difference of Kir2.1 protein in a whole cell preparation. The technique has been used before (30). Briefly, cell pellets were collected from 103 cells per sample and washed three times using FACS buffer (containing 3% fetal calf serum in 0.01 M phosphate-buffered saline with the addition of 1g/l NaCl). The samples were then incubated with rabbit anti-human Kir2.1 (1:200) for 1 h at 4°C. After three washes with FACS buffer, the samples were incubated with monoclonal FITC conjugated anti-rabbit IgG (1:20) at 4°C in the dark. After three washes with FACS buffer, they were ready for the FACS analysis. During flow cytometry, cells were analyzed with CellQuest software (Becton Dickinson, Sunnyvale, CA). For each run, 10,000 cells were collected. Signals were gated to exclude debris but include most dispersed cells. Histograms of fluorescence intensity were plotted against cell numbers (events). The percentage fluorescent density was measured.

EGF Treatment. IC and normal BUC were patch clamped, and four recordings were taken to establish a baseline conductance. Recombinant human EGF (R&D Systems, Minneapolis, MN) was then dissolved in the bath solution to a concentration of 20 ng/ml. The infusion was run over the bath plate at 5 ml/min. Recordings were taken from the beginning of the infusion every 30 s for 5–10 min.

The secondary protocol involved IC and normal BUC, pretreated and incubated with genistein in starvation medium at a concentration of 100 μmol for 10 min at 37°C. The genistein was then removed and replaced with standard bath solution. The cells were then patch clamped and a baseline recording was taken as described above. EGF was then infused at a concentration of 20 ng/ml as described above. Recordings were taken every 30 s for the requisite 5–10 min.

The tertiary protocol involved infusing EGF at 0.6, 2, 6, 20, and 60 ng/ml to establish a dose-response curve for normal BUC. Before infusion, the cells were patch clamped and baseline recordings were taken as described above. The infusion rate again was 5 ml/min, and recordings were taken every 30 s for 5–10 min.

Genistein treatment. The electrophysiological measurements were made in the manner previously described. Once a successful patch clamp was achieved on a BUC, recordings were taken every 30 s for 2 min for a total of four for each cell. These recordings were used as a baseline. Genistein (Sigma) was then dissolved in the bath solution to a concentration of 100 μM. This mixture was then infused onto the bath plate at a rate of 5 ml/min. Recordings were taken every 30 s for a period of 5 to 10 min. Only cells whose patch lasted the requisite time were included in the data.

HB-EGF treatment. IC BUC, after growing to confluence, had buffer changed to MEM plus t-glutamine (Mediatech) supplemented with 1 U/ml insulin, 1.25 μg/ml amphoterin B, 100 U/ml penicillin, 100 μg/ml streptomycin (GIBCO), and 20 ng/ml recombinant human HB-EGF (R&D Systems). Cells were patch clamped at 24 and 48 h after exposure to HB-EGF.

Statistics. Data are presented as means ± SE. Student’s t-test was used to compare the differences in the mean between IC and normal BUC.
RESULTS

Electrophysiological findings in normal BUC. We measured currents of 35 BUC from four different normal asymptomatic patients. For the majority of these cells (32/35), whole cell macroscopic currents were characterized by large inward currents at negative potentials, large outward currents at positive potentials, and a flat “plateau” region at intermediate potentials, typical of strongly rectified membrane current-voltage (I-V) curves (Fig. 1A). We measured the resting potential of normal BUC. These cells had resting potentials \( E_m = -65.7 \pm 3.7 \text{ mV} \) (12 cells) near \( K^+ \) equilibrium potential \( E_K = -67 \text{ mV} \) for an exterior potassium concentration of 10 mM, indicating that potassium channels determined most of the resting membrane conductance in these cells (Fig. 1A).

Inward currents negative to \( E_K \) were usually 300–500 pA \( (E_m = -140 \text{ mV}) \). These currents had reversed potentials close to \( E_K \), implying the currents were attributable to potassium channels. We applied Ba\(^{2+}\), a potassium channel blocker, into the bath solution. At the concentration of 1 mM, Ba\(^{2+}\) could inhibit >90% of the current, indicating that inward currents in normal BUC are chiefly composed of \( K^+ \)-specific currents (Fig. 1B).

Because of the strongly rectified properties of the inward currents, we sought to identify the underlying inward rectifying potassium channel family members using membrane patched recording in cell-attached configuration. Original records of single-channel currents obtained during hyperpolarizing test pulses to \(-40, -60, -80, \) and \(-100 \text{ mV} \) (holding potential, \( E_m = 0 \text{ mV} \)) are shown in Fig. 1C. Amplitude histograms were constructed of events obtained at potentials from \(-100 \) to \(-40 \text{ mV} \), and values (means \( \pm \text{ SE} \)) for six patches are plotted (Fig. 1D). Fit of the data indicated a slope conductance of 22.7 pS and an extrapolated reversal potential of \(-0.2 \text{ mV} \), which, given 145 mM \( K^+ \) in the pipette, was close to the estimated \( K^+ \) reversal potential of 0 mV. Identification of a strongly inward rectifying ~25-pS channel prompted us to consider that this channel might be the Kir2.1 inward rectifier channel.

At membrane potentials positive to \(-40 \text{ mV} \), outward currents were observed in nearly all BUC (Fig. 2A). The size of the outward currents varied over one to two orders of magnitude between cells, from tens of picoamperes to nanoamperes. In four cells studied, the large outward currents were partially blocked by charybdotoxin (100 nM, Fig. 2B) and iberiotoxin (100 nM, data not shown), suggesting the presence of a BK channel. Western blotting confirmed the existence of the BK channel (see Fig. 6B). The outward current that remained in the presence of charybdotoxin could be further blocked by external application of 5 mM 4-AP (Fig. 2C). Its electrophysiological and pharmacological properties suggested that this component was due to a typical delayed rectifier potassium (K\(_D\)) channel.

Altering extracellular KCl from 3 to 33 mM resulted in expected changes in the reversal potentials from \(-98 \) to \(-37 \text{ mV} \) in a normal BUC (Fig. 3). Membrane current was unaffected by the change in extracellular potassium concentration.

Electrophysiological properties of IC BUC. We measured the resting membrane potential of 10 IC BUC cultured from three different patients. In contrast to the normal BUC, the IC cells had significantly depolarized resting potentials \( E_m \) of IC BUC = \(-59.3 \pm 2.9 \text{ mV}, n = 10 \) vs. \( E_m \) of normal BUC = \(-65.7 \pm 3.7 \text{ mV}, n = 12; P < 0.05, Table 1)\).

The inward and outward currents in IC BUC (Fig. 4) were both significantly decreased compared with normal BUC (Fig. 1A). The macroscopic I-V curve in IC cells was weakly rectifying, rather than the strongly rectifying pattern in normal BUC. The differences in electrophysiological behaviors between normal and IC cells are summarized in Table 1. Because the \( E_{rev} \) in IC has been shifted away from \( E_K \) in IC BUC, this suggested a decrease in potassium conductance or increased chloride conductance.

Expression of Kir2.1 and BK in normal and IC BUC. RT-PCR results (Fig. 5) revealed bands with the expected length (600 bp) of Kir2.1 mRNA in normal and IC BUC. Figure 6A shows representative Western blots for Kir2.1 of BUC from three normal and three IC patients. This analysis revealed a band with a molecular mass of ~60 kDa, which corresponded to the position of the Kir2.1 positive control. There appeared to be less expression of Kir2.1 in normal compared with IC BUC. Figure 6B shows expression of BK from one normal and one IC patient.

Flow cytometric techniques were used and FACS analysis was performed to determine the expression difference of Kir2.1 protein in a whole cell preparation. Figure 7 shows representative fluorescent profiles of IC BUC and normal BUC expression of Kir2.1 using FACS. In the absence of Kir2.1 primary antibody and FITC-conjugated secondary antibody, BUC, arrested by size, were predominantly located in the 10\(^0\) to 10\(^1\) area (Fig. 7A). In the absence of either FITC-conjugated secondary antibody or Kir2.1 primary antibody, the fluorescence density patterns remained the same (data not shown). When the rat basophilic leukemia cells were used as a positive control for Kir2.1 (33), higher fluorescence density was observed in M1 region (Fig. 7B). With the use of this flow cytometry correlation and the same marked region for Kir2.1 expression criteria, cells from two normal patients and three IC patients were examined for Kir2.1 expression. Figure 7E lists the mean percentages of positive Kir2.1 fluorescence density. The differences in fluorescence density between IC and normal BUC were not statistically significant.

EGF decreased inward potassium current in normal BUC. EGF at 20 ng/ml was infused over 12 cells from two normal patients. The response was a 91.8 \( \pm 11.7\% \) reduction in inward
current. Figure 8A represents the significant decrease in inward potassium current when a normal cell was exposed to 20 ng/ml EGF. Figure 8B shows EGF dose-dependent inhibition of inward potassium current conductance in normal BUC. IC cells also were subjected to the same EGF exposure protocol, but a reduction of the already small current was unable to be measured (data not presented).

Genistein was then used to pretreat three normal BUC before EGF infusion. The genistein pretreated normal BUC showed only a 22.4 ± 7.9% reduction in current during EGF (20 ng/ml) infusion (Fig. 8Cd); thus genistein pretreatment was able to block EGF’s inhibitory effect on potassium conductance.

**Increases in IC BUC inward potassium current induced by the tyrosine kinase inhibitor genistein.** IC BUC from two different patients and normal BUC from one patient were used to test the effect of acutely infused genistein. Recordings were taken from a total of 11 cells, 4 from each of the two IC patients and 3 from the one normal patient. The inward current increased 76.4 ± 30.2% for the IC BUC compared with their baseline recordings. A representative tracing of an IC cell after treatment with genistein is shown in Fig. 9. The normal BUC showed a 20.6 ± 14.7% increase in conductance from baseline following genistein infusion. On average, <2 min of infusion time was needed to see the maximal increase in conductance for each cell. The cells were observed to return to baseline function ∼3 min following the cessation of the genistein infusion.

**Increases in IC BUC inward potassium current induced by HB-EGF treatment.** When IC BUC were treated with HB-EGF at 20 ng/ml, increases in inward rectifying potassium current were detected that correlated with the duration of HB-EGF exposure. I-V tracings from HB-EGF-treated IC BUC are depicted in Fig. 10. A summary of the inward current density and membrane potential changes with 24- and 48-h exposure to HB-EGF is presented in Table 2. There were significant changes in both inward current density and membrane potential. These changes in IC BUC shifted its phenotype toward normal BUC (compare Table 2 with Table 1).

**DISCUSSION**

The function of the bladder is simple in theory: urine storage and emptying. Traditionally, bladder function has been investigated to understand bladder emptying because the main focus has been on regulation of bladder smooth muscle contraction. However, the interval duration that the bladder must remain quiescent and relaxed significantly exceeds the amount of time that a bladder contracts. Therefore, identification of signals that can promote bladder storage is of utmost importance. Both smooth muscle and BUC can contribute bladder relaxant signals. The concept that BUC can mediate these signals and regulate bladder function is relatively recent (1, 2, 4, 17, 26, 28–31). However, the conceptual framework in which epithelial cells lining a hollow viscous organ regulate sensation or contractility of that organ has been proposed. Unlike previous investigations of BUC, which rely primarily on animal bladders, this study examined the electrophysiological characteristics of human BUC and furthermore specifically compares the differences between normal and diseased states. If one desires to understand bladder sensory abnormalities, understanding why IC patients exhibit augmented bladder sensation seems a logical approach. Animal models of augmented bladder sensation are typically created with chemical bladder irritants such as acetic acid or cyclophosphamide. These models, although useful in probing sensory pathways, have limited applicability in human bladder hypersensation syndromes in which the...
patients have not been exposed to either of these agents. There also is a feline IC model in which cats exhibit bladder symptoms similar to those of humans with IC (18).

Previously, it has been shown that BUC from IC patients have abnormalities including altered cytokine production and augmented purinergic signaling (13–15, 28, 30, 31). From these studies, it was noted that the phenotypic expression of cytokines and ATP measured in the supernatant from in vitro cultures of IC BUC correlated with the expression of these substances measured from clinical urine specimens. Since abnormalities in IC BUC persist with passage of cells in culture, which exhibit altered phenotypic expression of specific proteins, it was theorized that differences in membrane electrophysiological properties between IC and normal BUC could be measured.

Electrophysiological measurements on human BUC have not been previously reported. A strongly inward rectifying potassium current putatively mediated by Kir2.1 was detected in normal BUC. This current was diminished in IC cells, resulting in the IC cells being in a more depolarized state. Kir2.1 was expressed in both IC and normal BUC based on Western blots and FACS analyses. Interestingly, IC urine specimens have been reported to contain increased EGF, and IC BUC have been reported to produce increased EGF (13–14), and a link between EGF and Kir2.1 has been studied in other types of cells.

<table>
<thead>
<tr>
<th>Cell Type</th>
<th>Kir2.1 (% of expression)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Negative control</td>
<td>2.2%</td>
</tr>
<tr>
<td>RBL Positive control</td>
<td>98.9%</td>
</tr>
<tr>
<td>IC BUC</td>
<td>94.4%±1.0%</td>
</tr>
<tr>
<td>Normal BUC</td>
<td>87.8%±5.6%</td>
</tr>
</tbody>
</table>

Fig. 7. Fluorescence-activated cell sorting (FACS) analyses for Kir2.1 in BUC. A–D show representative histograms. A: Kir2.1 negative control (primary antibody negative and secondary antibody negative). B: Kir2.1 positive control from rat basophilic leukemia (RBL) cell line. C: IC BUC. D: normal BUC. E: summary of Kir2.1 expression from 3 IC BUC and 2 normal BUC. The data represent means ± SE of the percentage of the cell population expressing Kir2.1 in triplicate samples. There was no statistical difference ($P > 0.05$) between IC and normal BUC %expression.

Fig. 8. EGF decreases Kir2.1 conductance in normal BUC. A: control tracing depicts average of 12 normal BUC before EGF infusion. EGF tracing shows the decrease in current following the infusion of 20 ng/ml EGF in these same 12 cells. B: dose-response curve of EGF inhibition of Kir2.1 conductance. Percent inhibition was measured for 3 cells at each EGF dose. C: step pulse recording from −80 to +80 mV. a and b show the effect on normal BUC before and after the infusion of EGF, respectively. c and d show how this effect is ameliorated by 10 min of pretreatment with genistein.
Investigators have reported that EGF can acutely suppress Kir2.1 conductance, presumably by activation of tyrosine kinase that phosphorylates Kir2.1 (33). Increased secretion of EGF by cultured IC BUC (13) could explain the differences in electrophysiological measurements in IC compared with normal BUC. To test this hypothesis, we applied exogenous EGF to normal BUC. Indeed, this caused acute inhibition of the inward potassium current in a dose-dependent fashion (Fig. 8B). The inhibitory effect of EGF could be blocked by pretreatment of the normal BUC with genistein, a nonspecific tyrosine kinase inhibitor (Fig. 8B), suggesting that phosphorylation of Kir2.1 by tyrosine kinase activity plays a role in regulating inward potassium current in human BUC. Furthermore, we could increase potassium conductance in IC BUC with exposure to 100 μM genistein (Fig. 9), thus changing an IC cell to a more normal phenotype. Genistein is nonspecific, so it may not be useful as a therapeutic agent. The relationship of a cytokine affecting ion channel function has been shown to occur with transforming growth factor-β1 (TGF-β1) and Kir2.3 in reactive astrocytes from rats (24). TGF-β1 acutely depolarized the cells through inhibition of Kir2.3. This process was not dependent on gene transcription, because the astrocytes were depolarized within minutes of exposure to TGF-β1. This type of relationship is similar to that detected when EGF was added to normal BUC. IC BUC have decreased inward current, presumably from their native overexpression of EGF; however, the signals giving rise to this are uncertain but could result from the effects of APF (13–15). Therefore, another treatment option for IC may be to block expression or activity of APF.

Suppression of HB-EGF levels in the urine of IC patients and cultured IC BUC also has been described (13, 14). We therefore tested the hypothesis that exogenously added HB-EGF can ameliorate the decreased inward potassium conductance in IC BUC. HB-EGF at 20 ng/ml, which is on the same order of magnitude detected in normal human urine specimens, increased the inward potassium current (Fig. 10). This effect was associated with duration of HB-EGF exposure (Table 2) with longer exposure to HB-EGF resulting in more normalization of the altered phenotype.

![Image](http://ajpcell.physiology.org/)  
**Fig. 8.** Genistein increases inward rectifying current in IC BUC. A: IC BUC tracing is of an IC cell before genistein treatment. After 100 μM genistein exposure, there was increased conductance of Kir2.1. B: there was a significantly greater increase (P < 0.05) in the inward current in IC BUC exposed to genistein compared with normal (control) BUC.

![Image](http://ajpcell.physiology.org/)  
**Fig. 9.** Genistein increases inward rectifying current in IC BUC. A: IC BUC tracing is of an IC cell before genistein treatment. After 100 μM genistein exposure, there was increased conductance of Kir2.1. B: there was a significantly greater increase (P < 0.05) in the inward current in IC BUC exposed to genistein compared with normal (control) BUC.

![Image](http://ajpcell.physiology.org/)  
**Fig. 10.** Heparin-binding EGF-like growth factor (HB-EGF) increases inward rectifying current in IC BUC. As the duration of HB-EGF exposure increased, the magnitude of the inward current increased. Tracing a: IC BUC with no exposure to HB-EGF; tracing b: 24-h exposure to HB-EGF; tracing c: 48-h exposure to HB-EGF.

![Image](http://ajpcell.physiology.org/)  
**Table 2. Electrophysiological effects of HB-EGF on IC BUC**

<table>
<thead>
<tr>
<th>Exposure</th>
<th>Inward current density, pA/pF</th>
<th>Membrane potential, mV</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>No HB-EGF Exposure</td>
<td>24-h HB-EGF Exposure</td>
</tr>
<tr>
<td>12</td>
<td>5.84±2.44</td>
<td>7.15±2.09</td>
</tr>
<tr>
<td>6</td>
<td>−57.2±3.5</td>
<td>−62.7±4.3*</td>
</tr>
</tbody>
</table>

Values are means ± SE for n observations. Inward current density and membrane potential in IC BUC reverted to normal phenotype (compare with Table 1) with increased duration of exposure to heparin-binding EGF-like growth factor (HB-EGF). *P < 0.05 compared with no exposure to HB-EGF.
greater detail than BUC. Many ionic conductances have been described in vascular endothelial cells (20). In the human capillary endothelial cells, the inward rectifying current (11) is similar to what was detected in this study of human BUC. In both of these cell types, there is a strongly inward rectifying current with reversal potential near K\(^+\) equilibrium (Fig. 1A) that is blocked by Ba\(^{2+}\) (Fig. 1B), and the current amplitude is a function of extracellular K\(^+\) (Fig. 3).

The function of Kir2.1 in BUC is not known, but Kir2.1 has been proposed to function as a mechanical stress sensor in vascular endothelial cells because laminar shear stress induced one of the fastest responses in potassium conductance (10). Because the bladder is also subject to mechanical force from filling and emptying, perhaps Kir2.1 in BUC may have a similar role in regulating the bladder’s response to mechanical signals. An alteration in the conductance in Kir2.1 in IC BUC may alter the IC BUC’s ability to respond to the normal mechanical changes occurring within the bladder. Whether decreased conductance of Kir2.1 in IC BUC mediates bladder hyperalgesia is unknown at this point, but it is suggested by these results.

The vascular endothelial response to extracellular potassium also has been studied. It is known that extracellular potassium can mediate vasodilation through effects on inward rectifying potassium currents as well on release of endothelium relaxing factor (5, 7, 25). Interestingly, one of the clinical tests used to “diagnose” IC is the potassium sensitivity test in which intravesical potassium is infused into the IC patient’s bladder to determine whether there is an augmented sensory response (i.e., intense pain) (21). If patients respond to intravesical potassium (at 400 mM, which is a supraphysiological concentration even for urine) with severe pain, they are considered to have IC. Whether this pain is partly due to the observed decrease in inward potassium current in IC BUC preventing complete bladder relaxation (vis-à-vis vasodilation) is unknown. Another commonly suggested treatment for IC is to reduce urinary potassium levels, but this approach has not been validated in a controlled clinical trial.

Similar to the vasculature, the bladder urothelium has been described to release a relaxant factor. Investigators have described a urothelium-derived inhibitory factor of detrusor smooth muscle in the pig bladder (9). This factor did not appear to be nitric oxide, an adenosine nucleotide, catecholamine, GABA, or an aminergic sensitive to endothelium-derived hyperpolarizing factor. Whether human BUC release this factor, whether this factor is related to the inward potassium current, and whether the amount or activity of this factor differs between IC and normal BUC are all unknown at this time.

The decreased outward potassium current detected in IC BUC was not the focus of this particular study. The data suggest that BK channels mediate the outward current (Fig. 2). Several experiments have examined the effect of BK on bladder function based on studies on BK knockout mice (19). However, in these studies, the hypothesis is that the absence of BK in bladder smooth muscle cells resulted in the urinary incontinence phenotype in these animals. The function of BK in bladder urothelial cells was not studied in these BK knockouts.

In summary, this is the first report describing the presence of an inward rectifying potassium current with a conductance of the Kir2.1 channel in cultured human BUC. In IC BUC, this current is significantly reduced with the IC BUC existing in a more depolarized state. The electrophysiological phenotype of normal and IC BUC can be switched by exposing BUC to EGF, genistein, and HB-EGF. These data suggest that these growth factors and protein phosphorylation may modulate the inward potassium current in human BUC. Furthermore, these findings showed that intrinsic abnormalities are present in membrane properties of IC BUC.

ACKNOWLEDGMENTS

This work was supported by National Institute of Diabetes and Digestive and Kidney Diseases Grant R01 DK-59441, the American Foundation for Urologic Disease, and the Maryland Chapter of National Kidney Foundation.

REFERENCES


*AJP-Cell Physiol* • VOL 292 • JANUARY 2007 • www.ajpcell.org